The Effectiveness of Chitosan and Snail Seromucous as Anti Tuberculosis Drugs

Abstract

BACKGROUND: Tuberculosis (TB) disease is an infection caused by Mycobacterium tuberculosis (MTB) and is transmitted through sputum droplets of sufferers or suspect TB in the air. Chitosan has been widely used in the biomedical and pharmaceutical fields because it is a biocompatible, biodegradable, non-toxic, antimicrobial, and hydrating agent with positive effects on wound healing. Seromucous of snail has anti-tumor bioactivity and is non-toxic to lymphocyte cells, and can even stimulate lymphocyte proliferation. Seromucous of snail as glycoprotein containing carbohydrates; α-1 globulin-oromucoid fraction; glycans, peptides, glycopeptides, and chondroitin sulfate. AIM: This study was to determine the effectiveness of snail seromucous and chitosan as anti TB drugs (ATD) in vitro. METHODS: The research method is based on an experimental laboratory. MTB isolates in this research from sputum samples of patients suspected of TB in Surakarta Regional General Hospital. The stages of the study were performed MTB culture and identification, management sampling, and drug susceptibility testing. RESULTS: The research results showed chitosan 5%; a combination of chitosan 9% and snail seromucous 50% (ratio 1:1) is a microbicide against MTB TB patient isolates. Snail seromucous was ineffective as a microbicide against MTB TB patients. CONCLUSION: The effectiveness as a bactericide against MTB, chitosan, and its combination with snail seromucous has the potential to be an ATD alternative.